

July 21, 2026

The Manager – Listing
BSE Limited,
P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Subject: Resignation of Chief Financial Officer upon transition to a different role within AstraZeneca Group

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III thereto, we hereby inform that Ms. Bhavana Agrawal, Executive Director and Chief Financial Officer (‘CFO’) has communicated her resignation from the position of CFO (Key Managerial Personnel) of the Company with effect from the close of business hours on August 31, 2026, pursuant to her appointment to a regional role within the AstraZeneca Group.

A copy of the resignation letter is enclosed herewith as Annexure – A.

Further, the details as required under the SEBI Master Circular SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as Annexure – B.

Sincerely,

For AstraZeneca Pharma India Limited

Tanya Sanish
Company Secretary & Compliance Officer
ACS No. 25784

Date: July 20, 2026

To

The Managing Director and the Board of Directors

AstraZeneca Pharma India Limited

Subject: Resignation as Chief Financial Officer upon transition to a different role within AstraZeneca

I hereby communicate my resignation from the position of Chief Financial Officer of the Company with effect from the close of business hours on August 31, 2026, pursuant to my appointment to a regional role within AstraZeneca Group.

I request you to accept my resignation as per the above.

I sincerely thank each member of the Board, the senior management team and all my colleagues for their support during my tenure.

Thanking you,

Sincerely



Bhavana Agrawal

Sr. No.	Particulars	Resignation of Ms. Bhavana Agrawal
1.	Reason for change	Resignation from the position of Chief Financial Officer
2.	Date of Appointment/ Cessation/ Term of appointment	Close of business hours on August 31, 2026
3.	Brief Profile	Not applicable
4.	Shareholding, if any, in the Company	NIL
5.	Disclosure of Relationships between Directors	Not applicable